Abstract 424P
Background
Paraneoplastic leucomoid reaction (PLR) is well described entity where white blood cell (WBC) count increase ≥50000/mm3 in association with malignancy.It is known to be predictive of poor prognosis.Recent research works have demonstrated that there are relationships between PLR activated by intratumoral production of granulocyte colony stimulatory factor (G-CSF), the RAS/RAF/MEK pathway and tumorogenesis. It may even seen before diagnosis of malignancy. It is too important to understand the cause of high WBC count to start specific proper treatment or change treatment protocol because many clinicians delayed to start treatment that harmful for patients.
Methods
The study was an observational study. Study period was January 2022 to June 2022.
Results
Of total 350 patients, PLR was found in only 24 (6.86%).Age range of patients were from 32 years to 85 years and average was 60 years. Among them, carcinoma lung 6(25%) where 4(66.66%) patients were metastatic to liver and 2(33.33%) patient had localized disease; carcinoma gall bladder 4(16.66%) where 4(100%) had metastasis to liver; carcinoma unknown primary 4(16.66%); carcinoma buccal mucosa 4(16.66%); carcinoma cervix 2(8.33%); metastatic prostate cancer 2(8.33%) and carcinoma urinary bladder 2(8.33%).Infections were ruled out methodically by culture and sensitivity of blood, urine, bone marrow but none showed any growth. 14(58.33%) patients were on specific treatment and 41.67%) patients were on supportive management after PLR develop. 23(95.83%) patients developed PLR after diagnosis of cancer or during cancer treatment or many days thereafter. Only 1(4.17%) patient developed PLR before diagnosis of malignancy. WBC count ≥50000/mm3 were found in 23(95.83%) and only 1(4.67%) patient had 45000/ mm3. Neutrophil count ≥90% were documented in 14(58.33%) patients and ≥85% in 10(41.67%). Platelet count were found high in 12(50%). Bone marrow examinations16(66.67%) showed Neutrophilic leucocytosis in 14(87.5%) patients.Death from development of PLR from 4 days to 240 days and average time of death was documented within 72 days.
Conclusions
In developing countries, patients were underwent investigations repeatedly for a long period for PLR that delayed diagnosis, ultimately delayed treatment and we lost patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abdullah Al Mamun Khan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
YO11 - Satisfactory response after Rituximab-Bendamustin in Poor Performance Status Geriatric with Relapsed DLBCL
Presenter: Yasjudan Putra
Session: Poster viewing 06
YO12 - Allogeneic hematopoietic stem cell transplant in a case of acute myeloid leukaemia with end stage renal disease
Presenter: DEVYANI SURANGE
Session: Poster viewing 06
YO13 - Rosai-Dorfman Disease Presenting with Multiple Contiguous Lymphadenopathy: A Case Report
Presenter: Lean Marx Maaño
Session: Poster viewing 06
YO15 - Nasopharyngeal carcinoma in pregnancy: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO16 - New onset SIADH masquerading progression in esthesioneuroblastoma
Presenter: Muthu Manikandan
Session: Poster viewing 06
YO17 - Olfactory Neuroblastoma with Cervical Lymph Node Metastases in a 21- Year old Filipino Woman: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO18 - Challenges in Provision of Patient centered care with a Practical approach in a Resource-limited setting - Steven Johnson Syndrome – Toxic Epidermal Necrolysis (SJS-TEN) overlap related to Phenytoin use and review of logistical challenges related to care provision - a Case Report.
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO19 - Posterior Reversible Encephalopathy Syndrome associated with Pharmacological management of Bowel obstruction at the end of life – a review of two cases separated by 5 years
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO20 - A case of drug-induced large vessel vasculitis with hoarseness as the chief complaint caused by pegfilgrastim during chemotherapy
Presenter: Takuya Sato
Session: Poster viewing 06
YO23 - Neo-adjuvant immunotherapy in operable non-small cell lung carcinoma
Presenter: Padmini S N
Session: Poster viewing 06